trending Market Intelligence /marketintelligence/en/news-insights/trending/zbas0dc9vpdgqgmjxxt8hg2 content esgSubNav
In This List

Sarepta Therapeutics adds director

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Sarepta Therapeutics adds director

Sarepta Therapeutics Inc. has appointed Mary Ann Gray to the board.

Gray is president of Gray Strategic Advisors LLC, a biotechnology strategic planning and advisory firm. Previously, she was on the boards of Senomyx Inc., Juniper Pharmaceuticals Inc., TetraLogic Pharmaceuticals Corp. and ACADIA Pharmaceuticals Inc.

Cambridge, Mass.-based Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics, gene therapy and other genetic medicine approaches for treating rare neuromuscular diseases.